Novo Nordisk Launches Wegovy in UAE Amid Focus on Advanced Distribution Networks

Wegovy, the weight-loss medication developed by Novo Nordisk, has officially entered the UAE market, marking a shift in the regional pharmaceutical landscape toward advanced distribution and supply chain management. The medication's debut in the Emirates serves as a logistical template for the deployment of high-demand GLP-1 receptor agonists across the Middle East. Logistics and Regulatory Infrastructure The UAE entry for Wegovy centers on the country’s robust cold-chain infrastructure and the regulatory framework established by the Ministry of Health and Prevention (MoHAP). Due to the high global demand and specific storage requirements for semaglutide products, the UAE distribution model prioritizes secure, temperature-controlled supply lines to ensure product integrity and prevent the entry of counterfeit alternatives into the retail market. Logistics hubs in Dubai and Abu Dhabi are facilitating the movement of the medication from manufacturing sites to local pharmacies and clinical centers. This distribution strategy is designed to mitigate the supply shortages that have previously hampered the drug’s availability in North American and European markets, ensuring a consistent…